Counteractive effects of antenatal glucocorticoid treatment on D1 receptor modulation of spatial working memory

Psychopharmacology (Berl). 2016 Oct;233(21-22):3751-3761. doi: 10.1007/s00213-016-4405-8. Epub 2016 Aug 23.

Abstract

Rationale: Antenatal exposure to the glucocorticoid dexamethasone dramatically increases the number of mesencephalic dopaminergic neurons in rat offspring. However, the consequences of this expansion in midbrain dopamine (DA) neurons for behavioural processes in adulthood are poorly understood, including working memory that depends on DA transmission in the prefrontal cortex (PFC).

Objectives: We therefore investigated the influence of antenatal glucocorticoid treatment (AGT) on the modulation of spatial working memory by a D1 receptor agonist and on D1 receptor binding and DA content in the PFC and striatum.

Methods: Pregnant rats received AGT on gestational days 16-19 by adding dexamethasone to their drinking water. Male offspring reared to adulthood were trained on a delayed alternation spatial working memory task and administered the partial D1 agonist SKF38393 (0.3-3 mg/kg) by systemic injection. In separate groups of control and AGT animals, D1 receptor binding and DA content were measured post-mortem in the PFC and striatum.

Results: SKF38393 impaired spatial working memory performance in control rats but had no effect in AGT rats. D1 binding was significantly reduced in the anterior cingulate cortex, prelimbic cortex, dorsal striatum and ventral pallidum of AGT rats compared with control animals. However, AGT had no significant effect on brain monoamine levels.

Conclusions: These findings demonstrate that D1 receptors in corticostriatal circuitry down-regulate in response to AGT. This compensatory effect in D1 receptors may result from increased DA-ergic tone in AGT rats and underlie the resilience of these animals to the disruptive effects of D1 receptor activation on spatial working memory.

Keywords: Dopamine; Dopamine receptors; Memory; Prefrontal cortex; Schizophrenia.

MeSH terms

  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / pharmacology
  • Animals
  • Basal Forebrain / drug effects
  • Basal Forebrain / metabolism
  • Behavior, Animal / drug effects
  • Biogenic Monoamines / metabolism
  • Brain / drug effects*
  • Brain / metabolism
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism
  • Dexamethasone / pharmacology*
  • Dopamine / metabolism
  • Dopamine Agonists / pharmacology
  • Dopaminergic Neurons / metabolism
  • Female
  • Glucocorticoids / pharmacology*
  • Gyrus Cinguli / drug effects
  • Gyrus Cinguli / metabolism
  • Locomotion / drug effects
  • Male
  • Maze Learning / drug effects
  • Memory, Short-Term / drug effects*
  • Neostriatum / drug effects
  • Neostriatum / metabolism
  • Patch-Clamp Techniques
  • Prefrontal Cortex / drug effects
  • Prefrontal Cortex / metabolism
  • Pregnancy
  • Prenatal Exposure Delayed Effects
  • Rats
  • Receptors, Dopamine D1 / drug effects*
  • Receptors, Dopamine D1 / metabolism
  • Spatial Memory / drug effects*
  • Synaptic Transmission / drug effects

Substances

  • Biogenic Monoamines
  • Dopamine Agonists
  • Glucocorticoids
  • Receptors, Dopamine D1
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
  • Dexamethasone
  • Dopamine